

Chinese Journal of Pharmacovigilance ›› 2026, Vol. 23 ›› Issue (9): 968-973.
DOI: 10.19803/j.1672-8629.20260471
Previous Articles Next Articles
Qi Yue, Wang Fan, Guo Xiaojing#, Ye Xiaofei*
Received:2026-06-12
Online:2026-09-15
Published:2026-09-15
CLC Number:
Qi Yue, Wang Fan, Guo Xiaojing, Ye Xiaofei. Progress in applications of common data models in the medical field[J]. Chinese Journal of Pharmacovigilance, 2026, 23(9): 968-973.
| [1] Park W Y, Schmidt T S, Salvador G, et al. Breaking data silos: incorpora-ting the DICOM imaging standard into the OMOP CDM to enable multimodal research[J]. Journal of the American Medical Informatics Association, 2025, 32(10): ocaf091. [2] Hallinan C M, Ward R, Hart G K, et al.Seamless EMR data access: integrated governance, digital health and the OMOP-CDM[J]. BMJ Health & Care Informatics, 2024, 31(1): e100953. [3] Hripcsak G, Ryan P B, Duke J D, et al.Characterizing treatment pathways at scale using the OHDSI network[J]. Proceedings of the National Academy of Sciences of theUnited States of America, 2016, 113(27): 7329-7336. [4] Zhang Meng, Shen Peng, Liu Zhike, et al.Application status of observational medical outcomes partnership common data model in China[J]. Chinese Journal of Epidemiology(中华流行病学杂志), 2025, 46(5): 907-913. [5] Yu Y X, Zheng Y Q, Zhang M, et al.Attitudes toward common data models among Chinese biomedical professionals: a cross-sectional survey[J]. JMIR Medical Informatics, 2025, 13: e77603. [6] Desai R J, Marsolo K, Smith J, et al.The FDA sentinel real world evidence data enterprise (RWE-DE)[J]. Pharmacoepidemiology and Drug Safety, 2024, 33(10): e70028. [7] Adimadhyam S, Barreto E F, Cocoros N M, et al.Leveraging the capabilities of the FDA's Sentinel System to improve kidney care[J]. Journal of the American Society of Nephrology, 2020, 31(11): 2506-2516. [8] Taherifard E, Ross J S, Ramachandran R, et al.US Food and Drug Administration Sentinel Initiative and postmarket drug safety surveillance: a review[J]. JAMA Health Forum, 2026, 7(4): e260754. [9] Ma Danhua, Qi Yan, Song Xingfang, et al.Investigation on development status of adverse drug reaction monitoring sentinel sites in China[J]. Chin J New Drugs Clin Rem(中国新药与临床杂志), 2025, 44(10): 721-727. [10] Soper B C, Cadena J, Nguyen S, et al.Dynamic modeling of hospitalized COVID-19 patients reveals disease state-dependent risk factors[J]. Journal of the American Medical Informatics Association, 2022, 29(5): 864-872. [11] Carnahan R M, Waitman L R, Charlton M E, et al.Exploration of PCORnet data resources for assessing use of molecular-guided cancer treatment[J]. JCO Clinical Cancer Informatics, 2020(4): 724-735. [12] Mcdowell B D, O'rokke M A, Schroeder M C, et al. Implementing cancer registry data with the PCORnet common data model: the Greater Plains Collaborative experience[J]. JCO Clinical Cancer Informatics, 2024, 8: e2400196. [13] Dedhia K, Maltenfort M, Elden L, et al.Multi-institutional assessment of otitis media epidemiology using real-world data[J]. International Journal of Pediatric Otorhinolaryngology, 2024, 179: 111921. [14] Huang S D, Bamba V, Bothwell S, et al.Development and validation of a computable phenotype for Turner syndrome utilizing electronic health records from a national pediatric network[J]. American Journal of Medical Genetics Part A, 2024, 194A(4): e63495. [15] Bannett Y, Luo I, Azuero-Dajud R, et al.ADHD diagnosis and timing of medication initiation among children aged 3 to 5 years[J]. JAMA Network Open, 2025, 8(8): e2529610. [16] Klann J G, Abend A, Raghavan V A, et al.Data interchange using i2b2[J]. Journal of the American Medical Informatics Association, 2016, 23(5): 909-915. [17] Li Nan, Wang Miye, Zheng Tao, et al.Design and application of clinical disease database system based on poststructured technology[J]. Chinese Medical Equipment Journal(医疗卫生装备), 2024, 45(4): 20-26. [18] Ye Yajuan, Hu Bin, Zhang Kunli, et al.Construction of an annotated corpus for entities and relations of diabetes electronic medical records[J]. Journal of Chinese Information Processing(中文信息学报), 2023, 37(12): 17-25. [19] Cohen J M, Cesta C E, Kjerpeseth L, et al.A common data model for harmonization in the Nordic Pregnancy Drug Safety Studies (NorPreSS)[J]. Norsk Epidemiologi, 2021, 29(1): 117-123. [20] Cesta C E, Engeland A, Karlsson P, et al.Incidence of malformations after early pregnancy exposure to modafinil in Sweden and Norway[J]. JAMA, 2020, 324(9): 895-897. [21] Bjørk M H, Zoega H, Leinonen M K, et al.Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability[J]. JAMA Neurology, 2022, 79(7): 672-681. [22] Sniadecki J, Lucey K, Shiu D. Integration of clinical trial and real-world data: a case study examination of CDISC standards[J]. Journal of the Society for Clinical Data Management, 2023, 2(3): jscdm.128. [23] Bikkanuri M, Hamidi M, Zozus M N, et al.Measuring expressiveness of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM) for the American Burn Association Burn Care Quality Program Registry Real-World Data (RWD)[C]//Proceedings of the 35th Medical Informatics Europe Conference (MIE 2025), 2025. [24] Thurin N H, Pajouheshnia R, Roberto G, et al.From inception to ConcePTION: genesis of a network to support better monitoring and communication of medication safety during pregnancy and breastfeed-ing[J]. Clinical Pharmacology & Therapeutics, 2022, 111(1): 321-331. [25] Gkolfi D, Van Rijt-Weetink Y R J, Taavola-Gustafsson H, et al. Temporal changes in reporting of neurodevelopmental outcomes after maternal exposure to valproate: a contribution of the ConcePTION project[J]. Drug Safety, 2025, 48(12): 1399-1411. [26] Morris J K, Garne E, Loane M, et al.EUROlinkCAT protocol for a European population-based data linkage study investigating the survival, morbidity and education of children with congenital anomalies[J]. BMJ Open, 2021, 11(6): e047859. [27] Morris J K, Loane M, Wahlich C, et al.Hospital care in the first 10 years of life of children with congenital anomalies in six European countries: data from the EUROlinkCAT cohort linkage study[J]. Archives of Disease in Childhood, 2024, 109(5): 402-408. [28] Seaton S E, Rankin J, Cavero-Carbonell C, et al.The healthcare needs of children with Down syndrome in the first year of life: an analysis of the EUROlinkCAT data linkage study[J]. Paediatric and Perinatal Epidemiology, 2025, 39(5): 394-401. [29] Loane M, Morris J K, Garne E, et al.Recommendations for improving surveillance of congenital anomalies in Europe using healthcare databases[J]. Paediatric and Perinatal Epidemiology, 2025, 39(3): 277-284. [30] Jensen P B, Andersen J H, Ernst M T, et al.EpiCore: a common data model for pharmacoepidemiological studies in Denmark, Norway, and Sweden[J]. Pharmacoepidemiology and Drug Safety, 2025, 34(11): e70241. [31] Kostka K, Duarte-Salles T, Prats-Uribe A, et al.Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS[J]. Clinical Epidemiology, 2022, 14: 369-384. [32] Cho J, You S C, Lee S, et al.Application of epidemiological geographic information system: an open-source spatial analysis tool based on the OMOP common data model[J]. International Journal of Environmental Research and Public Health, 2020, 17(21): 7824. [33] Gulden C, Macho P, Reinecke I, et al.RecruIT: a cloud-native clinical trial recruitment support system based on Health Level 7 Fast Healthcare Interoperability Resources (HL7 FHIR) and the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM)[J]. Computers in Biology and Medicine, 2024, 174: 108411. [34] Wang Siqi, Li Zhaohe, Zhang Minguang, et al.Development and application of a core data set for bioequivalence trials based on CDISC standards[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2026, 42(2): 291-296. [35] Oh S W, Ko S J, Im Y S, et al.Data quality assessment for observational medical outcomes partnership common data model of multi-center[J]. Studies in Health Technology and Informatics, 2023, 302: 322-326. [36] Kim K H, Choi W, Ko S J, et al.Multi-center healthcare data quality measurement model and assessment using OMOP CDM[J]. Applied Sciences, 2021, 11(19): 9188. |
| [1] | JIANG Xiaofeng, YANG Shuting, BAI Liqin, QI Jun, HE Jianxiong, CHEN Wenge, LIANG Zuhong, LI Yu, YU Xiaoxia. Monitoring of Adverse Drug Reactions Caused by Hospital Preparations and Evaluation Systems [J]. Chinese Journal of Pharmacovigilance, 2025, 22(9): 1008-1011. |
| [2] | JIA Zhichao, HU Siyuan, LI Ruiben, XU Yaqian. Safety of Children’s Traditional Chinese Medicine Decoction Pieces in Clinical Application and Children’s Drug Development [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 324-328. |
| [3] | SUN Siman, JIANG Haiyan, FAN Xiaoyu, LI Wanfang, BAO Jie, WANG Chuan, JIN Hongtao. Research progress in anti-AIDS compound preparations [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 978-984. |
| [4] | GUO Shushu, JIANG Haiyan, FAN Xiaoyu, LI Wanfang, BAO Jie, MA Enlong, JIN Hongtao. Rationality of compound drug components against hypertension [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 973-977. |
| [5] | JIANG Haiyan, ZHOU Tianyu, FAN Xiaoyu, LI Wanfang, BAO Jie, JIN Hongtao. Challenges to the current development of fixed-dose antitumor drug combinations [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 961-966. |
| [6] | ZHAO Xiaolu, GAO Xiaoyang, ZHANG Chunyan, LI Mingqi, MA Yuehong. Effect of PPARγ in liver fibrosis and current development of its ligand drugs: research progress [J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 716-720. |
| [7] | LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006. |
| [8] | JIANG Jiandong. Development and clinical safety of paediatric medicines in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 1-6. |
| [9] | WANG Li, WANG Xiaomo, YANG Chenlu. Bias and control in the monitoring and evaluation of post-marketing drug using the medical big data [J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 239-243. |
| [10] | TENG Yingying, LI Chaiquan, XU Yang, TANG Xun, GAO Pei. Progress in the application of real-world data in post-market surveillance of medical devices [J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 233-238. |
| [11] | LI Xinxu, TANG Zhimin, ZHOU Jun, TAN Mingmin, LU Mingliang, WANG Jingzhao, WANG Jun. Common questions about statistics in communication between drug sponsors and regulators in China [J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 169-175. |
| [12] | WU Wenyu, XIAO Xiao, WU Jianru. The Practice and Thinking of Pharmacovigilance at the Municipal Level under COVID-19 [J]. Chinese Journal of Pharmacovigilance, 2020, 17(10): 688-691. |
| [13] | SUN Yu-xin, WEI Feng-fang , , YANG Yue, . Opportunities and Challenges for Real World Evidence Applied in Drug Regulation and Health Decision Making [J]. Chinese Journal of Pharmacovigilance, 2017, 14(6): 353-358. |
| [14] | WANG, Ling. Opportunities and Challenges in Using Medical Big Data to Monitor and Evaluate Drug Safety [J]. Chinese Journal of Pharmacovigilance, 2015, 12(11): 660-664. |
| [15] | HAI Ying. Methods and Significance of Constructing the Database of Adverse Drug Reaction Information [J]. Chinese Journal of Pharmacovigilance, 2011, 8(7): 410-412. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||